Global Cell-based Assays Market to Reach $1.6 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Cell-based Assays. The global market for Cell-based assays is forecast to reach US$1.6 billion by the year 2017. Major factors driving market growth include increased use in drug discovery industry, growing number of drug targets being screened, new and enhanced screening technologies, and increasing use in toxicity testing. Growing interest in cell-based assays is also being driven by the need for automation, advancements of cell-based systems through technological innovations, and high throughput screening systems.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Cell-based Assays: A Global Strategic Business Report

San Jose, CA (PRWEB) April 25, 2011

Cell-based assays are emerging as the preferred tools for screening potential drug compounds as they facilitate in gaining access to a number of therapeutic targets. Growth in the market for cell-based assays is driven primarily by the increasing number of drug targets being screened through genomics and proteomics applications. This, in turn, is driving the increasing use of cell-based assays and the related expenditure by players in the pharmaceutical and biotechnology sectors. Surge in demand for cell-based assays could be attributed to the increasing need for efficient and economical release of a drug into the market. Given the accuracy of data obtained through cell-based assays, more number of major pharmaceutical companies engaged in drug discovery and development are keen on using this technique for screening procedures. While a major proportion of research activities are centered on drug discovery, cell-based assays are also expected to find applications in various other fields, such as toxicology studies, diagnostics, molecular biology, genetics, biochemistry, and neuroscience, among others. Pharmaceutical and biotechnology companies are willing to employ cell-based assays in place of other in-vitro and biochemical assays in drug discovery, given the numerous applications of cell-based assays that include target identification as well as validation, the screening of compounds for biosafety and efficacy, and the monitoring of cellular events.

The US represents the largest market for cell-based assays, as stated by the new market research report on Cell-based Assays. Europe comes a close second, and also represents the fastest growing market with a compounded annual growth rate (CAGR) of about 12% over the analysis period. The global market for cell-based assays is likely to expand further due to the presence of a million proteins with unknown functions, and the need for improved drug development processes. Growing interest in cell-based assays is also being driven by the need for automation as well as advancements of cell-based systems, through technological innovations. The automation of cell-based systems is expected to simplify as well as enhance the efficiency of the drug discovery process.

A notable trend in the cell-based assays market is its use in the high throughput screening process, which witnessed substantial growth during the past few years. Nearly 50% of all the assays focused on primary high throughput screening (HTS), and about 55% concentrated on selectivity screens. HTS aims to detect the lead compounds that are highly potential drug candidates. HTS cell-based assays employ immortalized and transformed cell lines for improved screening of drug compounds. The use of cells with physiological advantages in high throughput screening is a growing trend in drug discovery. This trend is complimented by technological advancements that enable in addressing practical issues, such as cell abundance, reproducibility, microfluidics, label-free detection through label-free cell-based assays, and high-throughput confocal imaging.

Major players profiled in the report include Agilent Technologies Inc., BD Biosciences, Beckman Coulter Inc., BioVision Inc., Caliper Life Sciences Inc., Cisbio Bioassays, DiscoveRx Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare Life Sciences, Invitrogen Corporation, Millipore Corporation, PerkinElmer Inc., Promega Corporation, ProQinase GmbH, Thermo Fisher Scientific Inc., among others.

The research report titled “Cell-based Assays: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the market, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for cell-based assays for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. The report also analyses the US market for Cell-based Assays by the following product segments – Assay Kits (Functional Assays, Cell Death-Associated Assays, Cell Growth-Associated Assays), and Laboratory Automation. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Cell_Based_Assays_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
E-mail: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments